December 17, 2022 10:28 COMMUNIQUÉ FROM ICOAT MEDICAL AB’S (PUBL) EXTRAORDINARY GENERAL MEETING 16 DECEMBER 2022 Read more
October 19, 2022 17:00 The U.S. Food and Drug Administration has granted iCoat Medical Orphan Drug Designation for TUM012 in the United States Read more
October 11, 2022 13:00 ICOAT MEDICAL ANNOUNCES SECOND INTERIMDATA FROM ONGOING FIRST-IN-HUMAN TRIAL WITH NOVEL DRUG TUM012 Read more
August 10, 2022 ICOAT MEDICAL ANNOUNCES INTERIM DATA FROM ONGOING FIRST-IN-HUMAN TRIAL WITH NOVEL DRUG TUM012 Read more
June 16, 2022 COMMUNIQUÉ FROM ICOAT MEDICAL AB’S (PUBL) ANNUAL GENERAL MEETING 15 JUNE 2022 Read more
June 13, 2022 iCoat Medical to present at the 14th International Conference on Complement Therapeutics in Rhodes, Greece in June 2022 Read more
June 4, 2022 iCoat Medical to present at the 29th International Congress of The Transplantation Society in Buenos Aires, Argentina in September 2022 Read more
April 25, 2022 iCoat Medical’s Chief Medical Officer Alireza Biglarnia featured in article from Njurfonden Read more
April 21, 2022 The European Commission has granted iCoat Medical Orphan Drug Designation for TUM012 in the EU Read more
January 11, 2022 Mattias Springare joins iCoat Medical as CFO and Head of Investor Relations Read more